LadRx Highlights Patent Issued for Its LADR Technology

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.

Stephen Snowdy, PhD, the Company’s Chief Executive Officer stated:

“Our LADR-based drug candidates are designed to offer higher dosing of chemotherapeutic agents with lower side effects by targeting the chemotherapeutic agent to the tumor environment. Our maytansinoid drugs certainly meet that intent, with LADR-based maytansine being deliverable in animals at nearly 10-times the dosing of non-LADR maytansine. This latest patent adds to the comprehensive portfolio of intellectual property that protects our LADR-based drugs.”

Next-generation Cancer Drugs Based on LADR (“Linker Activated Drug Release”)

Our first-generation LADR-based drug candidate, Aldoxorubicin, has been out-licensed to Immunity Bio, Inc. and is in clinical trials for pancreatic cancer. Our next-generation LADR-based drug candidates employ an improved linker and highly potent chemotherapeutic agents. The Company’s pre-clinical drug candidates are based on this next-gen LADR design, namely LADR7-10. LADR7 and 8 employ the highly potent chemotoxin Auristatin E, while LADR9 and 10 employ another highly potent chemotoxin called Maytansine. LADR7-10 have demonstrated powerful anti-cancer activity in pre-clinical animal models in several different types of solid tumors, and have shown acceptable toxicity profiles. These compounds are positioned to move into IND-enabling activities, and could be IND-ready and into Phase 1 clinical trials in as little as 18 months from funding of the LADR program.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading “Risk Factors”, and current reports filed since the date of the LadRx’s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

About LadRx

LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC). LadRx Corporation’s website is www.ladrxcorp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005235/en/